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(57) ABSTRACT 
Reverse transcription-quantitative polymerase chain reaction 
(RT-qPCR) assays, systems, methods and kits for the age 
determination of an individual from bloodstains or samples of 
unknown origin. The methodology is based on gene expres-
sion profiling analysis in which novel human newborn fetal 
specific genes are identified by detecting the presence of 
appropriate messenger RNA species. 
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HBGl 
acactcgcttctggaacgtctgaggttatcaataagctcctagtccagacgccatgggtcatttcacagaggaggacaaggctac 
tatcacaagcctgtggggcaaggtgaatgtggaagatgctggaggagaaaccctgggaaggctcctggttgtctacccatgga 
cccagaggttctttgacagctttggcaacctgtcctctgcctctgccatcatgggcaaccccaaagtcaaggcacatggcaagaa 
ggtgctgacttccttgggagatgccacaaagcacctggatgatctcaagggcacctttgcccagctgagtgaactgcactgtgac 
aagctgcatgtggatcctgagaacttcaagctcctgggaaatgtgctggtgaccgttttggcaatccatttcggcaaagaattcac 
ccctgaggtgcaggcttcctggcagaagatggtgactgcagtggccagtgccctgtcctccagataccactgagctcactgccc 
atgattcagagctttcaaggataggctttattctgcaagcaatacaaataataaatctattctgctgagagatcac 
Figure 1 
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HBG2 
acactcgcttctggaacgtctgaggttatcaataagctcctagtccagacgccatgggtcatttcacagaggaggacaaggctac 
tatcacaagcctgtggggcaaggtgaatgtggaagatgctggaggagaaaccctgggaaggctcctggttgtctacccatgga 
cccagaggttctttgacagctttggcaacctgtcctctgcctctgccatcatgggcaaccccaaagtcaaggcacatggcaagaa 
ggtgctgacttccttgggagatgccataaagcacctggatgatctcaagggcaccmgcccagctgagtgaactgcactgtgac 
aagctgcatgtggatcctgagaacttcaagctcctgggaaatgtgctggtgaccgmtggcaatccatttcggcaaagaattcac 
ccctgaggtgcaggcttcctggcagaagatggtgactggagtggccagtgccctgtcctccagataccactgagctcactgccc 
atgatgcagagcmcaaggataggctttattctgcaagcaatcaaataataaatctattctgctaagagatcac 
Figure 2 
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HBGln 
acactcgcttctggaacgtctgaggttatcaataagctcctagtccagacgccatgggtcatttcacagaggaggacaaggctac 
tatcacaagcctgtggggcaaggtgaatgtggaagatgctggaggagaaaccctgggaaggctcctggttgtctacccatgga 
cccagaggttcmgacagcmggcaacctgtcctctgcctctgccatcatgggcaaccccaaagtcaaggcacatggcaagaa 
ggtgctgacttccttgggagatgccacaaagcacctggatgattcagagcmcaaggataggcmattctgcaagcaatacaaat 
aataaatctattctgctgagagatcac 
Sequence ID 1 
Figure 3 
U.S. Patent Apr. 27, 2010 Sheet 4of14 US 7,704,693 Bl 
HBG2n 
acactcgcttctggaacgtctgaggttatcaataagctcctagtccagacgccatgggtcatttcacagaggaggacaaggctac 
tatcacaagcctgtggggcaaggtgaatgtggaagatgctggaggagaaaccctgggaaggctcctggttgtctacccatgga 
cccagaggttctttgacagctttggcaacctgtcctctgcctctgccatcatgggcaaccccaaagtcaaggcacatggcaagaa 
ggtgctgacttccttgggagatgccataaagcacctggatgatctcaagggcacctttgcccagctgagtgaactgcactgagct 
cactgcccatgatgcagagctttcaaggataggctttattctgcaagcaatcaaataataaatctattctgctaagagatcac 
Sequence ID 2 
Figure 4 
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S15 
ggcagtctcgcgataactgcgcaggcgcggaccaaagcgatctcttctgaggatccggcaagatggcagaagtagagcagaa 
gaagaagcggaccttccgcaagttcacctaccgcggcgtggacctcgaccagctgctggacatgtcctacgagcagctgatgc 
agctgtacagtgcgcgccagcggcggcggctgaaccggggcctgcggcggaagcagcactccctgctgaagcgcctgcgc 
aaggccaagaaggaggcgccgcccatggagaagccggaagtggtgaagacgcacctgcgggacatgatcatcctacccga 
gatggtgggcagcatggtgggcgtctacaacggcaagaccttcaaccaggtggagatcaagcccgagatgatcggccactac 
ctgggcgagttctccatcacctacaagcccgtaaagcatggccggcccggcatcggggccacccactcctcccgcttcatccct 
ctcaagtaatggctcagctaataaaggcgcacatgactcc 
Sequence ID 3 
Figure 5 
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F 5' gaa-agc-tct-gaa-tca-tcc-agg-tg 3' 
Sequence ID 4 
US 7,704,693 Bl 
Figure 6 
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6F AM-ttt-gtg-gca-tct-ccc-aag-gaa-gtc-agc MGBNFQ 
Sequence ID 5 
Figure 7 
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R 5' agt-caa-ggc-aca-tgg-caa-gaa-g 3' 
Sequence ID 6 
Figure 8 
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F 5' gca-gtg-agc-tca-gtg-cag-ttc 3' 
Sequence ID 7 
Figure 9 
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6FAM-caa-agg ... tgc-cct-tga-gat-cat-cca-gg MGBNFQ 
Sequence ID 8 
Figure 10 
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R 5' ttc-ctt-ggg-aga-tgc-cat-aaa 3' 
Sequence ID 9 
Figure 11 
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F 5' cca-aag-cga-tct-ctt-ctg-agg-at 3 
Sequence ID 10 
Figure 12 
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VIC-cgg-caa-gat-ggc-aga-agt-aga-gca-gaa MGBNFQ 
Sequence ID 11 
Figure 13 
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R 5' acg-ccg-cgg-tag-gtg-aa 
Sequence ID 12 
Figure 14 
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1 
AGE DETERMINATION FROM BIOLOGICAL 
STAINS USING MESSENGER RNA 
PROFILING ANALYSIS 
2 
gations. Currently no reliable validated molecular tests are 
available for age determination. 
This is a Divisional of application Ser. No. 11/232,313 filed 5 
Sep. 21, 2005 now U.S. Pat. No. 7,276,340 and claims the 
benefit of priority from U.S. Provisional Application Ser. No. 
60/612,233 filed Sep. 22, 2004 the content of which is incor-
porated herein by reference. 
Numerous molecular theories have been investigated for 
their correlation with human ageing. Postulated molecular 
mechanisms include, inter alia, progressive damage to DNA, 
telomere shortening, long-lived protein glycation and reac-
tive oxygen species (ROS)-mediated oxidative damage to 
macromolecules. A major downfall to these approaches is 
that they are characterized by the "degenerative" ageing pro-
FIELD OF THE INVENTION 
This invention relates to a ribonucleic acid (RNA) based 
assay system for determining the biological age of an indi-
vidual from which a body fluid originated. 
SEQUENCE LISTING 
Appendix A is a sequence listing of mRNA and DNA 
sequences identified in FIGS. 1-14, the content of Appendix 
A is also submitted on a compact disc and is incorporated 
herein by reference. Attached hereto is one compact disc 
containing the following files: 
SEQ. 1 provides the mRNA sequence ofHBGl 
SEQ. 2 provides the mRNA sequence ofHBG2 
SEQ. 3 provides the mRNA sequence ofHBGln (Seq. ID 
1) 
SEQ. 4 provides the mRNA sequence ofHBG2n (Seq. ID 
2) 
SEQ. 5 provides the mRNA sequence of S15 (Seq. ID 3) 
SEQ. 6 provides the DNA sequence of an HBG ln primer 
(Seq. ID 4) 
10 cess, whereby as individuals increase in age the amount of 
damage also increases, this is especially characteristic of 
older aged individuals. From the forensic standpoint, how-
ever, it would be useful to be able to distinguish between 
individuals of all age groups and this may require the detec-
15 ti on of more subtle molecular changes. An alternate approach 
to age determination relies on epigenetic and developmental 
control of gene expression through messenger RNA (mRNA) 
profiling analysis. This theory of "developmental" ageing, 
would allow individuals to be categorized into various age 
20 groups, each correlated with a specific stage of human devel-
opment. 
The life-cycle of humans comprises a number of develop-
mentally recognized stages. As the human proceeds through 
these developmental stages, sub-sets of the 20-50 thousand 
25 human genes will be differentially expressed. Determining 
the global gene expression profile (or differential mRNA 
gene expression profile) present in a biological stain could 
reveal constellations of genes whose expression is correlated 
with a specific age. For example, identifying fetal hemoglo-
30 bin (HBG) and fetal specific regulating mRNA species, iso-
lating pubertal and pre-pubertal hormones and receptors or 
assaying for DNA damage and repair factors would be indica-
tive of newborn babies, adolescent teenagers and elderly indi-
viduals, respectively. 
SEQ. 7 provides the DNA sequences of an HBGln probe 
(Seq. ID 5) 
SEQ. 8 provides the DNA sequences of an HBG ln primer 35 
(Seq. ID 6) SUMMARY OF THE INVENTION 
SEQ. 9 provides the DNA sequences of an HBG2n primer 
(Seq. ID 7) 
SEQ. 10 provides the DNA sequences of an HBG2n probe 
40 (Seq. ID 8) 
A primary objective of the present invention is to provide 
two novel newborn specific fetal hemoglobin genes. 
A second objective of the present invention is to provide an 
mRNA based method for identifying the newborn specific 
genes present in a bloodstain. SEQ. 11 provides the DNA sequences of an HBG2n primer (Seq. ID 9) 
SEQ. 12 provides the DNA sequences of an S15 primer 
(Seq. ID 10) 
SEQ. 13 provides the DNA sequences of an S15 probe 
(Seq.ID!!) 
SEQ. 14 provides the DNA sequences of an S15 primer 
(Seq. ID 12) 
BACKGROUND AND PRIOR ART 
It is now a routine matter for forensic scientists to obtain 
the genetic profile of an individual from deoxyribonucleic 
acid (DNA) recovered from a biological stain deposited at a 
crime scene. However, in certain instances where there is no 
developed suspect as yet or there is no match with any data-
base sample, the DNA profile per se provides no meaningful 
information to investigators, with the notable exception of 
gender determination. To aid in these investigations another 
useful biometric that could provide important probative infor-
mation is the biological age of an individual. For example, the 
ability to provide investigators with information as to whether 
a DNA donor is a newborn baby, an adolescent teenager or an 
elderly individual could be useful in certain cases, particu-
larly those involving young children such as kidnappings or 
in providing additional intelligence during terrorist investi-
A third objective of the present invention is to provide a kit 
for the analysis of bloodstains to determine if a particular 
45 bloodstain originated from a newborn individual. 
A preferred method for identifying whether a stain con-
tains blood of a newborn human being, includes, obtaining a 
sample stain consisting of a body fluid from a human being, 
extracting total ribonucleic acid (tRNA) from the sample 
50 stain, treating the total RNA with an enzyme, initiating a 
reverse-transcription (RT) reaction by treating total RNA 
with random decamer primers and a reverse transcriptase 
enzyme to produce cDNA, amplifying the cDNA using 
HBGv-specific and HSK primers with corresponding fluo-
55 rescently labeled probes, identifying the age of the donor by 
determining the cycle threshold (Ct) value of a housekeeping 
gene (HSK) and the Ct value of the HBGv target gene, then 
subtracting the Ct value of the target gene, from the Ct value 
of the HSK gene, wherein a positive value would indicate that 
60 the blood originates from a newborn human being. 
A more preferred method uses the reverse transcriptase 
enzyme, Moloney Murine Leukemia Virus (MMLV-RT) and 
has 2 variants of hemoglobin (HBG) used as primers. The 2 
variants ofHBG are HBG ln and HBG2n and the primers are 
65 segments ofHBG ln and HBG2n. More preferably, the prim-
ers are one or more selected from the sequence ID 4, 5, 6, 7, 
8, 9, 10, 11or12. 
US 7,704,693 Bl 
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The preferred identifying probes fluoresce and the values 
are determined by finding the Ct of the HSK and the Ct of each 
of the variants of HBG and then subtracting the Ct of the 
HBGv from the Ct of the HSK, generating a dCt value. The 
HSKis the ribosomal protein, S15 and the age of the newborn 5 
is less than 1 week old or the age of the newborn can be less 
than 5 months old. More preferably, the HSK is glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH). 
The life-cycle of humans comprises a number of develop-
mentally recognized stages. As the human proceeds through 
these developmental stages, sub-sets of the 20-50 thousand 
human genes will be differentially expressed. Determining 
the global gene expression profile (or differential mRNA 
gene expression profile) present in a biological stain could 
reveal constellations of genes whose expression is correlated 
with a specific age. For example, identifying fetal hemoglo-
bin and fetal specific regulating mRNA species, isolating 
pubertal and pre-pubetal hormones and receptors or assaying 
for DNA damage and repair factors, would be indicative of 
The preferred extracting procedure for the total RNA uses 
a denaturing solution such as guanidine isothiocyanate-phe- 10 
nol:chloroform. Preferably, the extracted total RNA is pre-
cipitated with an organic solvent, such as, isopropanol. The 
preferred enzyme used to treat the extracted total RNA is 
deoxyribonuclease I (DNase I). 
newborn babies, adolescent teenagers and elderly individu-
als, respectively. 
A clear example of age related differential gene expression 
involves the fetal to adult hemoglobin shift. The human beta-
hemoglobin locus is located on the short arm of chromosome 
11 (llp15.5), and encodes five functional beta-like globin 
genes: epsilon, gammaG, ganimaA, delta, and beta, (hemo-
globin ganima mRNA sequences, HBGl (ganimaA) and 
A preferred gene coding for the human newborn specific 15 
fetal hemoglobin variant is HBGln as in SEQ ID 1 and 
HBG2n as in SEQ ID 2. 
Another preferred gene coding for the human newborn 
specific fetal hemoglobin variants are HBGln and HBG2n 
and polymorphisms thereof. 
A preferred kit for use in determining the biological age of 
20 HBG2 (gammaG), are provided in FIG. 1 and FIG. 2, respec-
tively). 
an individual in an unknown bloodstain, uses HBGln and 
HBG2n and HSK specific primers, preferably, selected from 
one or more of sequence ID 4, 5, 6, 7, 8, 9, 10, 11, or 12; the 
preferred housekeeping gene is the ribosomal protein, S15. 25 
The preferred probes are labeled with fluorescent dyes. 
The expression of embryonic hemoglobin (epsilon) com-
mences in the yolk sac in the early stages of gestational 
development. During the fifth week of gestation the fetal liver, 
spleen and bone marrow begin to express the fetal specific 
gamma hemoglobin chains (ganimaA and gammaG) to form 
Further objects and advantages of this invention will be 
apparent from the following detailed description and example 
of a presently preferred embodiment. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 provides the mRNA sequence ofHBGl 
FIG. 2 provides the mRNA sequence ofHBG2 
FIG. 3 provides the mRNA sequence ofHBGln 
FIG. 4 provides the mRNA sequence ofHBG2n 
FIG. 5 provides the mRNA sequence ofS15 
FIG. 6 provides the DNA sequence of an HBG ln primer 
FIG. 7 provides the DNA sequences of an HBG ln probe 
FIG. 8 provides the DNA sequences of an HBG ln primer 
FIG. 9 provides the DNA sequences of an HBG2n primer 
FIG. 10 provides the DNA sequences of an HBG2n probe 
FIG. 11 provides the DNA sequences of an HBG2n primer 
FIG.12 provides the DNA sequences of an S15 primer 
FIG.13 provides the DNA sequences of an S15 probe 
FIG.14 provides the DNA sequences of an S15 primer 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
Before explaining the disclosed embodiments of the 
present invention in detail it is to be understood that the 
invention is not limited in its application to the details of the 
particular arrangements shown since the invention is capable 
the fetal hemoglobin protein. This up-regulation of gamma-
globin is accompanied by a shutdown of epsilon-globin syn-
thesis. Shortly before birth, beta-globin gene expressioncom-
30 mences in the bone marrow, forming adult hemoglobin and 
inturn ganima-globin expression is down regulated. There-
fore, the development of an assay which identifies ganima 
hemoglobin mRNA in a biological stain, would indicate that 
35 
the donor of the stain is a newborn baby. 
The gamma hemoglobin locus was analyzed by reverse 
transcription-polymerase chain reaction (RT-PCR) using two 
sets of highly specific primers, one designed to specifically 
amplify HBG 1 (gammaA) and one designed for amplification 
of HBG2 (gammaG). In contrast to our initial hypothesis, a 
40 messenger RNA (mRNA) product corresponding to the indi-
vidual HBG 1 or HBG2 genes was amplified in all age groups 
tested. These results demonstrated that the production of 
gamma hemoglobin mRNA is not restricted to the fetal and 
newborn stages of development. Upon further investigation 
45 of these RT-PCR assays, the presence of an additional lower 
molecular weight amplimer was detected in only newborn 
individuals. These lower molecular weight products were 
excised, cloned, sequenced and aligned with the standard 
hemoglobin genes. Alignment analysis revealed these lower 
50 molecular weight amplimers to be variants of the standard 
gamma hemoglobin genes (HBGv) which we have termed 
HBGln and HBG2n (variant ganima hemoglobin mRNA 
sequences HBGln and HBG2n are provided in FIG. 3 and 
FIG. 4, respectively). 
of other embodiments. Also, the terminology used herein is 55 
for the purpose of description and not of limitation. 
Based on this process the invention provides real-time PCR 
duplexes which are composed of one novel newborn specific 
fetal hemoglobin variant, HBGln or HBG2n, whose 
sequences are identified as SEQUENCE ID 1 (HBG ln) (FIG. 
3), SEQUENCE ID 2 (HBG2n) (FIG. 4), and one housekeep-
Below is a listing of several acronyms used herein: 
DNA is deoxyribonucleic acid 
Ct is cycle threshold value; it is the cycle number at which the 
fluorescent signal passes a pre-determined threshold. 
HBG is hemoglobin 
HSK is housekeeping gene 
RNA is ribonucleic acid 
mRNA is messenger ribonucleic acid 
ROS is reactive oxygen species 
RT-PCR is reverse transcription polymerase chain reaction 
S15 is ribosomal protein 
60 ing gene (HSK), which may be the ribosomal protein, S15, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 
others (example ofa HSK gene sequence, S 15, (SEQUENCE 
ID 3) (FIG. 5)). The collection of genes that are expressed 
within the constellation of differentiated cells that make up a 
65 body fluid is called the multicellular transcriptome. These 
genes comprise ubiquitously expressed housekeeping (HSK) 
genes, which are responsible for cell maintenance functions 
US 7,704,693 Bl 
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independent of biological age, and genes that are specifically 
expressed in an age dependent manner. 
Fluorescent (i.e. FAM (6-carboxyfluorescein) and VIC) 
dye-labeled probes (i.e. minor groove binding non-fluores-
cent quencher (MGBNFQ)) and their corresponding unla- 5 
beled primers are incorporated into the real-time PCR 
( qPCR) reaction. These qPCR duplexes have been optimized 
to determine if a bloodstain originated from a newborn indi-
vidual and are sensitive with as little as 50 pg of input RNA 
(intotheqPCRreaction). Thereal-timeqPCRmethodologyis 10 
based on determining the delta cycle threshold (dCt) values 
generated using the cycle threshold (Ct) of the HSK gene and 
the Ct of the novel hemoglobin variants (HBGv) (dCt=Ct 
S15-Ct HBGv). A positive dCt value would indicate a new-
born origin; in contrast a negative dCt value would be 15 
obtained with all other ages. 
An mRNA based approach for age determination, such as 
the real time PCR assays described above, could allow the 
facile identification of the newborn specific genes present in 
a bloodstain and could rapidly become a validated molecular 20 
test for newborn specific age determination. 
As an example, the assay of the invention can be performed 
in two fashions: one in which the newborn is identified as less 
than 1 week old; the other as less than 5 months old, depend-
ing on the amount of material used. 25 
The following example provides further explanation of the 
present invention. 
Example 1 
30 
For RNA isolation, total RNA is extracted from a blood-
stain using a denaturing solution, composed of guanidine 
isothiocyanate, the RNA is isolated with acid phenol:chloro-
form and precipitated with isopropanol and GlycoB!ue™ 
glycogen carrier (fromAmbion Inc., Austin, Tex.). The RNA 35 
is centrifuged and the pellet is washed once with a 75% 
ethanol/25% DEPC-treated water solution. The pellet is 
dried, re-solubilized and stored in an RNAsecure Resuspen-
sion Solution (Ambion Inc.,Austin, Tex.). Next, the extracted 
total RNA is treated with an enzyme, deoxyribonuclease I 40 
(TURBO™ DNase (RNase-Free)) (Ambion Inc., Austin, 
Tex.), quantitated using the unsymmetrical cyanine dye 
RiboGreen® (Molecular Probes, Eugene, Oreg.) and then 
reverse-transcribed using fifty micromolar random decamers 
as the first strand primer, producing complementary DNA 45 
(cDNA). The Moloney Murine Leukemia Virus-Reverse 
Transcriptase enzyme (MMLV-RT) from Ambion Inc., Aus-
tin, Tex., was used in this case. Finally, the cDNA is amplified 
using housekeeping and newborn gene-specific primers (as 
exemplified in FIGS. 6-14). 50 
Based on the above extraction and purification technique, 
duplex real-time PCR assays using in this case the Taqman® 
Universal PCR Master Mix in the 7000 Sequence detection 
System from Applied Biosystems, Foster City, Calif., and 
standard cycling conditions such as: Step 1: 1 cycle of 50 55 
degrees C., for 2:00 minutes; Step 2: 1 cycle of95 degrees C., 
for 10:00 minutes; Step 3: 40-50 cycles of95 degrees C., for 
0: 15 seconds and 60 degrees C., for 1 :00 minute; wherein data 
is collected at stage 3, step 2 (60 degrees C., for 1:00) were 
developed which can definitively identify newborn RNA. 60 
These duplex reactions are composed of one of the two novel 
variant forms of newborn gamma hemoglobin (HBGv), 
HBGln or HBG2n, and a housekeeping (HSK) gene, the 
ribosomal protein, S 15 and have been optimized for the detec-
tion of newborn individuals from bloodstains. The method- 65 
ology is based on gene expression profiling analysis in which 
the HBGv genes are identified by detecting the presence of 
6 
appropriate mRNA species. The gene-specific primers are 
incorporated with fluorescently labeled probes (i.e. FAM and 
VIC) into a single multiplexed quantitative polymerase chain 
reaction ( qPCR). The mRNA is amplified and this amplifica-
tion is detected by determining the fluorescent emission of the 
dye-labeled probe. 
Example 2 
In an assay of the invention which identifies newborns that 
are from 1 hour to 1 week in biological age one may proceed 
as Example 1 above using: 
HBGln 
50 nanomolar of each primer (Forward and Reverse) 
250 nanomolar of the probe 
HBG2n 
50 nanomolar of each primer (Forward and Reverse) 
250 nanomolar of the probe 
S15 
900 nanomolar of each primer (Forward and Reverse) 
250 nanomolar of the probe 
Example 3 
In an assay of the invention which identifies newborns that 
are from 1 hour to 5 months in biological age one may pro-
ceed as in Example 1 above using: 
HBGln 
100 nanomolar of each primer (Forward and Reverse) 
250 nanomolar of the probe 
HBG2n 
50 nanomolar of each primer (Forward and Reverse) 
250 nanomolar of the probe 
S15 
600 nanomolar of each primer (Forward and Reverse) 
250 nanomolar of the probe 
Example 4 
The cycle threshold (Ct) values obtained are used to deter-
mine the delta Ct (dCt) for that particular sample. The equa-
tion for dCt calculation is: 
Ct(S 15)-Ct(HBG ln)~dCt 
Ct(S 15)-Ct(HBG2n)~dCt 
If the dCt value is positive then the sample originated from 
a newborn. 
If the dCt value is negative then the sample originated from 
an age other than newborn. 
If no Ct value is generated with the newborn genes (HBG ln 
or HBG2n) the sample is given a Ct value of 40.000 (the 
maximum number of cycles), for that particular gene. If no Ct 
value is generated with the housekeeping gene (Sl 5) than the 
assay must be repeated. 
US 7,704,693 Bl 
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While the invention has been described, disclosed, illus-
trated and shown in various terms of certain embodiments or 
modifications which it has presumed in practice, the scope of 
the invention is not intended to be, nor should it be deemed to 
be, limited thereby and such other modifications or embodi-
ments as may be suggested by the teachings herein are par-
ticularly reserved especially as they fall within the breadth 
and scope of the claims here appended. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 14 
<210> SEQ ID NO 1 
<211> LENGTH, 584 
<212> TYPE, DNA 
<213> ORGANISM, HBGl 
<400> SEQUENCE, 1 
acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc 60 
atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag 120 
atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct 180 
ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg 240 
cacatggcaa gaaggtgctg acttccttgg gagatgccac aaagcacctg gatgatctca 300 
agggcacctt tgcccagctg agtgaactgc actgtgacaa gctgcatgtg gatcctgaga 360 
acttcaagct cctgggaaat gtgctggtga ccgttttggc aatccatttc ggcaaagaat 420 
tcacccctga ggtgcaggct tcctggcaga agatggtgac tgcagtggcc agtgccctgt 480 
cctccagata ccactgagct cactgcccat gattcagagc tttcaaggat aggctttatt 540 
ctgcaagcaa tacaaataat aaatctattc tgctgagaga tcac 584 
<210> SEQ ID NO 2 
<211> LENGTH, 583 
<212> TYPE, DNA 
<213> ORGANISM, HGB2 
<400> SEQUENCE, 2 
acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc 60 
atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag 120 
atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct 180 
ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg 240 
cacatggcaa gaaggtgctg acttccttgg gagatgccat aaagcacctg gatgatctca 300 
agggcacctt tgcccagctg agtgaactgc actgtgacaa gctgcatgtg gatcctgaga 360 
acttcaagct cctgggaaat gtgctggtga ccgttttggc aatccatttc ggcaaagaat 420 
tcacccctga ggtgcaggct tcctggcaga agatggtgac tggagtggcc agtgccctgt 480 
cctccagata ccactgagct cactgcccat gatgcagagc tttcaaggat aggctttatt 540 
ctgcaagcaa tcaaataata aatctattct gctaagagat cac 583 
<210> SEQ ID NO 3 
<211> LENGTH, 367 
<212> TYPE, DNA 
<213> ORGANISM, HBGln 
<400> SEQUENCE, 3 
acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc 60 
atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag 120 
atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct 180 
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-continued 
ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg 240 
cacatggcaa gaaggtgctg acttccttgg gagatgccac aaagcacctg gatgattcag 300 
agctttcaag gataggcttt attctgcaag caatacaaat aataaatcta ttctgctgag 360 
agatcac 367 
<210> SEQ ID NO 4 
<211> LENGTH, 421 
<212> TYPE, DNA 
<213> ORGANISM, HBG2n 
<400> SEQUENCE, 4 
acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc 60 
atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag 120 
atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct 180 
ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg 240 
cacatggcaa gaaggtgctg acttccttgg gagatgccat aaagcacctg gatgatctca 300 
agggcacctt tgcccagctg agtgaactgc actgagctca ctgcccatga tgcagagctt 360 
tcaaggatag gctttattct gcaagcaatc aaataataaa tctattctgc taagagatca 420 
c 421 
<210> SEQ ID NO 5 
<211> LENGTH, 531 
<212> TYPE, DNA 
<213> ORGANISM, S15 
<400> SEQUENCE, 5 
ggcagtctcg cgataactgc gcaggcgcgg accaaagcga tctcttctga ggatccggca 60 
agatggcaga agtagagcag aagaagaagc ggaccttccg caagttcacc taccgcggcg 120 
tggacctcga ccagctgctg gacatgtcct acgagcagct gatgcagctg tacagtgcgc 180 
gccagcggcg gcggctgaac cggggcctgc ggcggaagca gcactccctg ctgaagcgcc 240 
tgcgcaaggc caagaaggag gcgccgccca tggagaagcc ggaagtggtg aagacgcacc 300 
tgcgggacat gatcatccta cccgagatgg tgggcagcat ggtgggcgtc tacaacggca 360 
agaccttcaa ccaggtggag atcaagcccg agatgatcgg ccactacctg ggcgagttct 420 
ccatcaccta caagcccgta aagcatggcc ggcccggcat cggggccacc cactcctccc 480 
gcttcatccc tctcaagtaa tggctcagct aataaaggcg cacatgactc c 531 
<210> SEQ ID NO 6 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, HBGln 
<400> SEQUENCE, 
gaaagctctg aatcatccag gtg 23 
<210> SEQ ID NO 7 
<211> LENGTH, 27 
<212> TYPE, DNA 
<213> ORGANISM, HBGln 
<400> SEQUENCE, 7 
tttgtggcat ctcccaagga agtcagc 27 
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<210> SEQ ID NO 8 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, HBGln 
<400> SEQUENCE, 8 
agtcaaggca catggcaaga ag 
<210> SEQ ID NO 9 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, HBG2n 
<400> SEQUENCE, 9 
gcagtgagct cagtgcagtt c 
<210> SEQ ID NO 10 
<211> LENGTH, 26 
<212> TYPE, DNA 
<213> ORGANISM, HBG2n 
<400> SEQUENCE, 10 
caaaggtgcc cttgagatca tccagg 
<210> SEQ ID NO 11 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, HBG2n 
<400> SEQUENCE, 11 
ttccttggga gatgccataa a 
<210> SEQ ID NO 12 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, S15 
<400> SEQUENCE, 12 
ccaaagcgat ctcttctgag gat 
<210> SEQ ID NO 13 
<211> LENGTH, 27 
<212> TYPE, DNA 
<213> ORGANISM, S15 
<400> SEQUENCE, 13 
cggcaagatg gcagaagtag agcagaa 
<210> SEQ ID NO 14 
<211> LENGTH, 17 
<212> TYPE, DNA 
<213> ORGANISM, S15 
<400> SEQUENCE, 14 
acgccgcggt aggtgaa 
We claim: 
1. An isolated gene coding for the human newborn specific 
fetal hemoglobin variant HBGln as in SEQ ID3. 
2. An isolated gene coding for the human newborn specific 
fetal hemoglobin variant HBG2n as in SEQ ID 4. 
65 
22 
21 
26 
21 
23 
27 
17 
3. A kit for use in determining the biological age of an 
individual 
in an unknown bloodstain, comprising HBGln and 
HBG2n and HSK specific primers and probes wherein 
the primers are selected from the group consisting of one 
or more of SEQ ID 6, and 9. 
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4. A kit, as in claim 3, wherein said housekeeping gene is 
the ribosomal protein S15. 
5. A kit, as in claim 3, wherein said probes are selected from 
the group consisting of one or more of Sequence ID 7 and 
Sequence IDlO. 
6. A kit, as in claim 3, wherein said probes are labeled with 
fluorescent dyes. 
14 
7. An isolated forward primer for the human newborn 
specific fetal hemoglobin variant HBGln as in SEQ ID 6. 
8. An isolated forward primer for the human newborn 
specific fetal hemoglobin variant HBG2n as in SEQ ID 9. 
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